Upsher-Smith adds to generic portfolio

Print Friendly, PDF & Email
MAPLE GROVE, MN – Upsher-Smith Laboratories, LLC (Upsher-Smith) has added another product to its growing generic portfolio, supporting its commitment to expanding and diversifying its product offerings.

Upsher Smith has launched four new products and two line extensions this year. Upsher-Smith’s Bexarotene Capsules, 75 mg, an AB-rated generic version of the branded product, Targretin (bexarotene) Capsules, was approved by the U.S. Food and Drug Administration (FDA) on July 25.

“This is an exciting time for Upsher-Smith. Our portfolio is more diversified than ever before and we are optimistic that we will continue to grow given the record number of potential ANDA submissions planned over the next several years and key strategic partnerships we’ve formed,” said Rusty Field, president and chief executive officer, Upsher-Smith.



Comments are closed.